Cytovance Biologics Inc. Appoints Don Wuchterl As Chief Operating Officer

Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company, announced the promotion of Donald Wuchterl to Chief Operating Officer. In this new capacity, Mr. Wuchterl will oversee Cytovance's Research & Development Services, Manufacturing & Warehouse, Facilities, Engineering, and Program Management functions. Mr. Wuchterl joined Cytovance in July of 2012 as the Sr. Vice President of Manufacturing Operations. In that brief time, he's made significant contributions to Cytovance, demonstrating a commitment to improving systems, facilities, and personnel.
Mr. Wuchterl has built up an accomplished and empowered team that significantly contributed to Cytovance's doubling in size in the last two years. In addition to organizational improvements, Mr. Wuchterl also plays a major leadership role to enabling Cytovance's continued growth and expansion. This includes the construction and qualification/validation of several new production suites as well as a new Greenfield Manufacturing and GMP Warehousing facility that will greatly increase Cytovance's scale, service offerings, and technical capabilities. "I have had the distinct pleasure of knowing Don for many years and feel he is the ideal candidate for this position. His knowledge and experience with both clinical and commercial biologics manufacturing, along with his years of working in the design and validation of biologics facilities makes him an invaluable asset to Cytovance's Leadership team," said CEO Darren Head.

Donald Wuchterl has over 22 years of experience manufacturing clinical and commercial GMP products including biologics, small molecules, and cellular immunotherapies. Mr. Wuchterl has extensive experience in the design, validation, licensure, and operation of these facilities. Prior to joining Cytovance, Mr. Wuchterl was Director of Manufacturing at Dendreon, responsible for the construction, start-up, and operation of their cellular immunotherapy manufacturing facility in Union City, Georgia. Previous to Dendreon, Mr. Wuchterl held the position of Director of Manufacturing at Shire, Human Genetic Therapies where he had General Manager Responsibilities for the end user design and start-up of Shire's Lexington, Massachusetts facility expanding their enzyme replacement therapy manufacturing capacity. Previous to Shire, Mr. Wuchterl held several positions of increasing responsibility with Amgen at their facilities in Colorado, Rhode Island, and Cork Ireland. Additionally, Mr. Wuchterl worked for Biogen Idec and Roche early in his career. Mr. Wuchterl holds a Bachelor's of Science degree in Business Administration from Colorado Technical University.

"I am honored to be recognized by Darren Head, President and CEO of Cytovance, and the Board of Directors in expanding my role on Cytovance's Executive Leadership Team," said Donald Wuchterl. "I have the benefit of working with an incredibly talented organization with standout performers at every level. I look forward to working with our executive team, the operations leadership team, the quality unit, and our gifted employees as we continue into the next phase of the company's evolution. Combining all of the 'execution' facets of the Cytovance organization under one umbrella will improve performance, reduce silo effects, and ultimately provide a better customer experience."

Cheryl Tuck
Marketing Communications Manager
Email Contact

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.